Noninvasix is pioneering a groundbreaking approach to the non-invasive monitoring of central venous oxygenation, a critical indicator of sepsis and septic shock severity. Their patented optoacoustic platform technology enables continuous and real-time measurement of central venous saturation, which is essential for diagnosing and managing tissue hypoxia in critically ill patients. By integrating this technology into ICU workflows, Noninvasix aims to enhance the speed and accuracy of sepsis diagnosis, allowing healthcare providers to tailor treatments effectively and improve patient outcomes. The potential applications of this technology extend beyond sepsis, with future uses anticipated in areas such as fetal monitoring, neonatal care, traumatic brain injury, and conditions associated with blood loss and anemia.

The urgency of addressing sepsis is underscored by its life-threatening nature, where the body's response to infection can lead to severe organ dysfunction and potentially fatal outcomes. Noninvasix's mission is to meet the critical need for early detection and monitoring of sepsis, thereby significantly improving patient care and reducing healthcare costs. Their innovative monitoring system is designed to identify key indicators of septic shock as early as possible, facilitating timely intervention to mitigate complications and enhance survival rates. While the optoacoustic technology is not yet FDA approved and is currently unavailable in the U.S., its development represents a significant advancement in the fight against sepsis.

United States

Noninvasix will be the first company to monitor the severity of sepsis and septic shock non-invasively, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real time.   Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose critically ill patients and tailor treatments to improve outcomes. 

Future developments, enhancements, and evidence will expand our technology's use and clinical impact in other indications and settings.  

Noninvasix is backed by 15 years of optoacoustic research and more than $6.5 million in research grants.

Noninvasix

Company Details